Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-09

Clinical Trial Update: Selegiline to Zelapar Switch Study in Parkinson Disease Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating a switch from selegiline to Zelapar in Parkinson's disease patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Selegiline (selegiline)
  • ZELAPAR (SELEGILINE HYDROCHLORIDE)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Parkinson's Disease | Phase 4 | Status: COMPLETED | Results posted: 2023-08-09